Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https://www.sciencedirect.com/science/article/pii/S0305737220300554

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, IMbrave150 Investigators (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905. https://www.nejm.org/doi/10.1056/NEJMoa1915745?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9–22. https://faseb.onlinelibrary.wiley.com/doi/full/https://doi.org/10.1096/fasebj.13.1.9

Article  CAS  PubMed  Google Scholar 

Cosmai L, Gallieni M, Liguigli W, Porta C (2017) Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). J Nephrol 30(2):171–180. https://link.springer.com/article/10.1007/s40620-016-0311-8

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE (2008) VEGF Inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11):1129–1136. https://www.nejm.org/doi/full/https://doi.org/10.1056/nejmc080770

Article  CAS  PubMed  PubMed Central  Google Scholar 

Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic Inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30(2):187–200. https://jasn.asnjournals.org/content/30/2/187.long

Article  CAS  PubMed  PubMed Central  Google Scholar 

Camarda N, Travers R, Yang VK, London C, Jaffe IZ (2022) VEGF receptor inhibitor-Induced hypertension: emerging mechanisms and clinical implications. Curr Oncol Rep 24(4):463–474. https://link.spriranger.com/article/10.1007/s11912-022-01224-0

Nihei S, Asaka J, Takahashi H, Kudo K (2021) Bevacizumab Increases Endothelin-1 Production via Forkhead Box Protein O1 in Human Glomerular Microvascular Endothelial Cells In Vitro. Int J Nephrol. 2021:8381115. https://doi.org/10.1155/2021/8381115

Nihei S, Asaka J, Yaegashi M, Asahi K, Kudo K (2024) Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study. J Pharm Health Care Sci 10(1):51. https://jphcs.biomedcentral.com/articles/https://doi.org/10.1186/s40780-024-00372-8

Article  PubMed  PubMed Central  Google Scholar 

Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Aikata H (2022) Risk factors for early onset of proteinuria in patients receiving Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Liver Cancer 12(3):251–261. https://karger.com/lic/article/12/3/251/836202/Risk-Factors-for-Early-Onset-of-Proteinuria-in

Article  PubMed  PubMed Central  Google Scholar 

Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H (2021) Early tumor response and safety of Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice. Cancers 13(16):3958. https://www.mdpi.com/2072-6694/13/16/3958

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kumada T, 48 clinics in Japan) (2022) Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma a landmark analysis. Hepatol Res 52(5):462–470. https://doi.org/10.1111/hepr.13748

Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kikuchi Y, Kogure T, Yumita S, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Taida T, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Shinozaki M, Kato J, Kato N (2023) Clinical effects and emerging issues of Atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. Cancer 129(4):590–599. https://doi.org/10.1002/cncr.34559

Article  CAS  PubMed  Google Scholar 

Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher TF, Shechter M, Taddei S, Vita JA, Lerman A (2012) The assessment of endothelial function: from research into clinical practice. Circulation 126(6):753–767. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.112.093245?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A (2004) Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 44(11):2137–2141. https://www.sciencedirect.com/science/article/pii/S0735109704017541?via%3Dihub

Article  PubMed  Google Scholar 

Koo BK, Chung WY, Moon MK (2020) Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study. Cardiovasc Diabetol 19(1):82. https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01062-z

Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, Aso Y (2016) Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol 15:76. https://doi.org/10.1186/s12933-016-0396-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steeghs N, Rabelink TJ, op ’t Roodt J, Batman E, Cluitmans FHM, Weijl NI, de Koning E, Gelderblom H (2010) Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 21(5):1100–1105. https://www.sciencedirect.com/science/article/pii/S0923753419392063?via%3Dihub

Sena CM, Gonçalves L, Seiça R (2022) Methods to evaluate vascular function: a crucial approach towards predictive, preventive, and personalised medicine. EPMA J 13(2):209–235. https://link.springer.com/article/10.1007/s13167-022-00280-7

Sueta D, Suyama K, Sueta A, Tabata N, Yamashita T, Tomiguchi M, Takeshita T, Yamamoto-Ibusuki M, Yamamoto E, Izumiya Y, Kaikita K, Yamamoto Y, Hokimoto S, Iwase H, Tsujita K (2017) Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: potential role of vascular endothelial dysfunction. Atherosclerosis 260:116–120. https://www.sciencedirect.com/science/article/pii/S0021915017301429?via%3Dihub

Article  CAS  PubMed  Google Scholar 

Tanaka A, Tomiyama H, Maruhashi T, Matsuzawa Y, Miyoshi T, Kabutoya T, Kario K, Sugiyama S, Munakata M, Ito H, Ueda S, Vlachopoulos C, Higashi Y, Inoue T, Node K (2018) Physiological diagnosis criteria for vascular failure committee. Physiological diagnostic criteria for vascular failure. Hypertension 72(5):1060–1071. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.118.11554?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Terwoord JD, Beyer AM, Gutterman DD (2022) Endothelial dysfunction as a complication of anti-cancer therapy. Pharmacol Ther 237:108116. https://www.sciencedirect.com/science/article/abs/pii/S0163725822000109?via%3Dihub

Lai S, Amabile MI, Mazzaferro S, Mitterhofer AP, Mazzarella A, Galani A, Imbimbo G, Cianci R, Pasquali M, Molfino A, Study Group on Geriatric Nephrology of the Italian Society of Nephrology (SIN) (2020) Effects of Sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma. Cancer Med 9(11):3752–3757. https://doi.org/10.1002/cam4.2910

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steeghs N, Gelderblom H, Roodt JOT, Christensen O, Rajagopalan P, Hovens M, Putter H, Rabelink TJ, De Koning E (2008) Hypertension and rarefaction during treatment with Telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 14(11):3470–3476. https://aacrjournals.org/clincancerres/article/14/11/3470/72699/Hypertension-and-Rarefaction-during-Treatment-with

Article  CAS  PubMed  Google Scholar 

Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA (2011) Contrary effects of the receptor tyrosine kinase inhibitor Vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 58(1):85–92. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.110.168120?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, Baelde HJ, Danser AH, van den Meiracker AH (2014) Treatment of hypertension and renal injury induced by the angiogenesis inhibitor Sunitinib: preclinical study. Hypertension 64(6):1282–1289. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.114.04187?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Endemann DH, Schiffrin EL (2004) Endothelial dysfunction. J Am Soc Nephrol 15(8):1983–1992. https://journals.lww.com/jasn/abstract/2004/08000/endothelial_dysfunction.3.aspx

Article  CAS  PubMed  Google Scholar 

Nihei S, Ikeda T, Aoki T, Murasato F, Yaegashi M, Asahi K, Kudo K (2023) Plasma endothelin-1 May predict bevacizumab-induced proteinuria in patients with colorectal cancer. Cancer Chemother Pharmacol 91(5):427–434. https://doi.org/10.1007/s00280-023-04532-9

Article  CAS  PubMed  Google Scholar